Randomized, double-blind, comparator-controlled crossover trial (n=30) testing low-dose IV ketamine (0.5 mg/kg, 40 min infusion) versus midazolam in patients with OCD at the Medical University of Vienna.
Randomized, double-blind, triple-masked crossover study comparing a single IV ketamine infusion (0.5 mg/kg over 40 minutes) with midazolam in adults with primary OCD; sequences separated by a 14-day washout and stratified by baseline YBOCS severity.
Outcomes include acute and short-term anti-OCD effects, neurocognitive performance on four tasks, stress responsivity using a cold pressor test, and EEG measures during and after infusions.
An optional open-label continuation offers up to eight ketamine infusions over a month compared with treatment-as-usual; additional EEG assessment follows completion of open-label treatment.
Single IV infusion of ketamine (0.5 mg/kg) in crossover; optional open-label continuation (up to 8 infusions).
Diluted in 100 ml saline; infused over 40 minutes.
Open-label continuation phase (optional).
Comparator infusion of midazolam (0.045 mg/kg) administered IV over 40 minutes.
Midazolam comparator; diluted in 100 ml saline; infused over 40 minutes.
Standard-of-care treatment at physician discretion (psychotherapy, pharmacotherapy, physiotherapy, ergotherapy or combination).
Treatment as usual (TAU) comparator for open-label phase.